- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech High Growth Potential Companies
U.S. Pharmaceuticals & Biotech High Growth Potential Companies
UPDATED Feb 04, 2023
Companies with a Future performance score of at least 3, ordered by Future performance score.
137 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| SRPTSarepta Therapeutics | US$119.00 | -3.2% | 62.8% | US$10.4b | US$149.44 | PS11.9x | E56.4% | n/a | ||
| ITCIIntra-Cellular Therapies | US$48.92 | 2.5% | 0.4% | US$4.6b | US$70.00 | PS24.6x | E62.1% | n/a | ||
| CTICCTI BioPharma | US$5.63 | -1.6% | 177.3% | US$714.4m | US$11.41 | PS21.7x | E55.2% | n/a | ||
| EOLSEvolus | US$9.54 | -6.9% | 13.8% | US$536.6m | US$16.56 | PS3.8x | E61.2% | n/a | ||
| FOLDAmicus Therapeutics | US$13.25 | 3.3% | 46.9% | US$3.7b | US$15.36 | PS11.5x | E58.1% | n/a | ||
| CARACara Therapeutics | US$12.26 | 2.2% | 15.0% | US$658.8m | US$23.63 | PS16.7x | E58.0% | n/a | ||
| ENTAEnanta Pharmaceuticals | US$52.50 | 0.9% | -14.4% | US$1.1b | US$68.70 | PS12.7x | E61.7% | n/a | ||
| TGTXTG Therapeutics | US$17.36 | 18.7% | 71.0% | US$2.3b | US$19.11 | PS462.5x | E53.0% | n/a | ||
| BLFSBioLife Solutions | US$26.07 | 10.9% | -5.7% | US$1.1b | US$31.00 | PS7.2x | E61.1% | n/a | ||
| MDGLMadrigal Pharmaceuticals | US$279.79 | -3.4% | 296.5% | US$5.0b | US$303.00 | PB467.9x | E63.8% | n/a | ||
| ACADACADIA Pharmaceuticals | US$19.83 | 6.8% | -16.0% | US$3.2b | US$18.74 | PS6.3x | E61.5% | n/a | ||
| KMPHKemPharm | US$5.59 | 1.5% | -14.7% | US$192.9m | US$19.25 | PS18x | E59.8% | n/a | ||
| PCRXPacira BioSciences | US$41.86 | 6.2% | -35.0% | US$1.9b | US$67.00 | PE92x | E25.0% | n/a | ||
| ENSCEnsysce Biosciences | US$0.72 | 2.1% | -97.8% | US$8.2m | US$6.65 | PS3x | E46.1% | n/a | ||
| CKPTCheckpoint Therapeutics | US$5.64 | 11.5% | -76.4% | US$111.4m | US$102.60 | PS831.4x | E57.2% | n/a | ||
| AGRXAgile Therapeutics | US$0.27 | -0.5% | -98.1% | US$10.9m | US$2.00 | PS1.3x | E59.3% | n/a | ||
| OLKOlink Holding | US$19.95 | 1.4% | 18.8% | US$2.5b | US$23.00 | PS19.6x | E58.0% | n/a | ||
| CVMCEL-SCI | US$2.68 | -2.2% | -52.1% | US$117.1m | US$14.50 | PB3.6x | E66.2% | n/a | ||
| CTKBCytek Biosciences | US$13.39 | 12.2% | -5.6% | US$1.8b | US$16.50 | PS11.7x | E60.3% | n/a | ||
| HALOHalozyme Therapeutics | US$52.65 | 3.8% | 56.2% | US$7.1b | US$56.22 | PE33.7x | E28.7% | n/a | ||
| CAPRCapricor Therapeutics | US$4.16 | -1.9% | -1.9% | US$102.8m | US$15.00 | PS64.6x | E58.8% | n/a | ||
| AMLXAmylyx Pharmaceuticals | US$36.64 | -10.5% | 62.7% | US$2.4b | US$48.80 | PS7036.6x | E56.5% | n/a | ||
| OPTNOptiNose | US$1.75 | -1.7% | -27.4% | US$192.2m | US$5.60 | PS2.5x | E60.0% | n/a | ||
| URGNUroGen Pharma | US$9.27 | -0.9% | 26.5% | US$214.0m | US$28.40 | PS3.4x | E56.1% | n/a |